| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EBITDA | -8,9 k € | +20.4% | -11,2 k € | -35.4% | -8,3 k € | -4.6% | -7,9 k € | +8.5% | -8,7 k € | -36.2% | -6,4 k € | +37.2% | -10,1 k € | -4.9% | -9,6 k € | -46.5% | -6,6 k € | +14.0% | -7,7 k € | +9.7% | -8,5 k € | -14.4% | -7,4 k € | +5.3% | -7,8 k € | -106.2% | -3,8 k € | +33.9% | -5,7 k € | -0.3% | -5,7 k € | +75.2% | -23,1 k € | -46.0% | -15,8 k € | -337.5% | -3,6 k € | |
| Operating profit | -8,9 k € | +20.4% | -11,2 k € | -35.4% | -8,3 k € | -4.6% | -7,9 k € | +8.5% | -8,7 k € | -36.2% | -6,4 k € | +37.2% | -10,1 k € | -4.9% | -9,6 k € | -46.5% | -6,6 k € | +14.0% | -7,7 k € | +9.7% | -8,5 k € | -14.4% | -7,4 k € | +5.3% | -7,8 k € | -106.2% | -3,8 k € | +33.9% | -5,7 k € | -0.3% | -5,7 k € | +79.4% | -27,8 k € | -35.4% | -20,5 k € | -146.7% | -8,3 k € | |
| Profit/loss | -12,8 k € | +29.7% | -18,2 k € | -119.5% | -8,3 k € | -4.6% | -7,9 k € | +8.5% | -8,7 k € | -36.2% | -6,4 k € | +37.3% | -10,1 k € | +2.8% | -10,4 k € | -46.9% | -7,1 k € | +12.9% | -8,2 k € | +5.8% | -8,7 k € | -14.5% | -7,6 k € | +3.3% | -7,8 k € | -117.6% | -3,6 k € | +37.2% | -5,7 k € | -2.9% | -5,6 k € | -15.0% | -4,8 k € | +92.9% | -67,9 k € | -4.8% | -64,8 k € | |
| Equity | 17,6 M € | -0.1% | 17,7 M € | -0.1% | 17,7 M € | -0.0% | 17,7 M € | -0.0% | 17,7 M € | -0.0% | 17,7 M € | -0.0% | 17,7 M € | -0.1% | 17,7 M € | -0.1% | 17,7 M € | -0.0% | 17,7 M € | -0.0% | 17,7 M € | -0.0% | 17,7 M € | -0.0% | 17,8 M € | -0.0% | 17,8 M € | -0.0% | 17,8 M € | -0.0% | 17,8 M € | +2.7% | 17,3 M € | +11.6% | 15,5 M € | -0.4% | 15,6 M € | |
| Total assets | 17,7 M € | -0.0% | 17,7 M € | +0.0% | 17,7 M € | 0.0% | 17,7 M € | 0.0% | 17,7 M € | 0.0% | 17,7 M € | 0.0% | 17,7 M € | -0.0% | 17,7 M € | -0.2% | 17,8 M € | -0.0% | 17,8 M € | -0.0% | 17,8 M € | -0.0% | 17,8 M € | -0.0% | 17,8 M € | -0.0% | 17,8 M € | -0.0% | 17,8 M € | -0.0% | 17,8 M € | +2.7% | 17,3 M € | +3.5% | 16,7 M € | +7.3% | 15,6 M € | |
| Cash | 362,1 € | -76.5% | 1,5 k € | — | — | — | — | — | — | 36,6 k € | +3723.7% | 956,9 € | -33.9% | 1,4 k € | -10.6% | 1,6 k € | -8.3% | 1,8 k € | -2.2% | 1,8 k € | +13.3% | 1,6 k € | -63.8% | 4,4 k € | -37.1% | 7,0 k € | +430.5% | 1,3 k € | -86.4% | 9,7 k € | ||||||||
| Debts | 86,5 k € | +12.7% | 76,8 k € | +39.1% | 55,2 k € | +17.6% | 46,9 k € | +20.3% | 39,0 k € | +28.5% | 30,4 k € | +26.5% | 24,0 k € | +73.2% | 13,9 k € | -65.4% | 40,0 k € | +19.7% | 33,4 k € | +29.7% | 25,8 k € | +49.2% | 17,3 k € | +75.5% | 9,8 k € | +383.6% | 2,0 k € | -59.3% | 5,0 k € | +149.7% | 2,0 k € | -60.2% | 5,0 k € | -99.6% | 1,2 M € | +199851.9% | 605,0 € | |
Public limited company · Merelbeke-Melle · incorporated on 27/05/2004
Public limited company loss-making in the latest fiscal year. Cash position declining (-76.5%).
Solid counterparty for a standard engagement.
JUBILANT PHARMA is a Public limited company incorporated in 2004. Its registered office is in Merelbeke-Melle.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette